Mar 20, 2018

Kalytera Initiates Program to Develop a Novel Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) today announced that it is has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been filed in the U.S. and other jurisdictions, and Kalytera has obtained an exclusive, worldwide license for this compound from Beetlebung Pharma, Ltd., an Israeli-based pharmaceutical discovery company focused on cannabinoid-based therapeutics for the treatment of human disease (“BPL”). https://kalytera.co/news/cannabinoid-based-compound-for-acute-and-chronic-pain-program-initiation/

Jan 31, 2018

Kalytera Announces Grant of Stock Options

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (KALTF) (the “Company” or “Kalytera”) today announced that it has granted stock options on January 30, 2018 to certain directors and officers of the Company. The stock options have an exercise price of $0.38 per common share and expire ten years from the date of grant. https://kalytera.co/news/grant-of-stock-options/

Jan 26, 2018

Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel

Kalytera Therapeutics, Inc. (KALY.V) (KALTF) (the “Company” or “Kalytera”) today announced that the Company has elected to issue 396,015 common shares of the Company (“Common Shares”) to The Salzman Group in payment of an invoice issued under the services agreement with The Salzman Group previously announced on December 7, 2017 (the “Agreement”). Under the Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease. https://kalytera.co/news/issuance-of-shares-under-services-agreement-with-the-salzman-group-of-israel/

Jan 11, 2018

Kalytera Announces Settlement of Debt Transactionces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel

Kalytera Therapeutics, Inc. (KALY.V) (KALTF) (the “Company” or “Kalytera”) today announced that it has entered into an agreement to pay amounts owing to a service provider for past services in common shares of the Company (“Common Shares”). The transaction is subject to approval by the TSX Venture Exchange (“TSXV”). https://kalytera.co/investors/news-archive/?2018

Dec 22, 2017

Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (KALTF) (the “Company” or “Kalytera”) today announced that the TSX Venture Exchange (“TSXV”) has approved the arrangement reached with The Salzman Group of Israel to allow Kalytera, at its option, to pay invoices under a services agreement with The Salzman Group in common shares of the Company (“Common Shares”). As previously announced on December 7, 2017, Kalytera has entered into a services agreement with The Salzman Group (the “Agreement”), under which The Salzman Group will provide clinical study management services in relation to the Phase 2 study, including chemistry, manufacturing and controls (“CMC”) analytics, as well as stability studies, toxicology studies and drug-drug interaction studies, all of which will be required by the FDA to be completed prior to initiation of a Phase 3 pivotal study. https://kalytera.co/news/kalytera-announces-approval-of-shares-for-services-and-settlement-of-debt-transaction-with-the-salzman-group-of-israel/

Dec 20, 2017

Kalytera Announces Closing of Brokered Private Placement

Kalytera Therapeutics, Inc. (TSX Venture: KALY) (OTCQB:KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of its previously announced brokered private placement offering (the “Offering”) of CDN$5,750,000 aggregate principal amount of convertible debenture units at a price of CDN$1,000 per convertible debenture unit, which includes the full exercise by the Echelon Wealth Partners Inc. (“Echelon”) of its option to sell an additional 750 convertible debenture units. Echelon acted as agent for and on behalf of the Company in connection with the Offering. The net proceeds of the Offering will be used by the Company to advance its Phase 2 clinical program evaluating the use of cannibidiol in the prevention of graft versus host disease, as well as for general corporate purposes. https://kalytera.co/news/kalytera-announces-closing-of-brokered-private-placement/ 

Dec 07, 2017

Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the “Company” or “Kalytera”) today announced the initiation of a Phase 2 clinical study evaluating the use of cannabidiol (“CBD”) in the prevention of graft versus host disease (“GVHD”). Kalytera also announced today that it has entered into an agreement with The Salzman Group of Israel, under which The Salzman Group will, among other things, accept common shares of Kalytera in payment for its services in connection with the Phase 2 study, subject to TSX Venture Exchange approval. https://kalytera.co/news/initiation-of-phase-2-clinical-study-in-prevention-of-gvhd-and-agreement-with-the-salzman-group/

Dec 05, 2017

Kalytera Confirms No Material Change in Operations

At the request of IIROC, Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the “Company” or “Kalytera“) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity. https://kalytera.co/news/kalytera-confirms-no-material-change-in-operations/

Nov 27, 2017

Kalytera Announces Second US Patent for Prevention and Treatment of Graft Versus Host Disease

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a second patent covering the use of cannabidiol (“CBD”) in the prevention and treatment of graft versus host disease (“GVHD”). https://kalytera.co/news/second-us-patent-for-prevention-and-treatment-of-gvhd/

Nov 22, 2017

Kalytera Announces $5 Million Private Placement of Convertible Debenture Units

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (KALTF) (the “Company” or “Kalytera”) announced today that it has entered into an agreement with Echelon Wealth Partners Inc. (“Echelon” or the “Agent”), to lead a brokered best efforts private placement of up to $5,000,000 aggregate principal amount of convertible debenture units (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit (the “Offering”). Each Convertible Debenture Unit will consist of: (i) $1,000 principal amount of 9.0% secured convertible debentures (the “Convertible Debentures”); and (ii) 3,846 common share purchase warrants (each whole warrant, a “Warrant”) of the Company (representing 50% warrant coverage on each Convertible Debenture). https://kalytera.co/news/kalytera-announces-5-million-private-placement-of-convertible-debenture-units/

Nov 15, 2017

Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Diseaseounces Robert Farrell, J.D. as CEO; Additional Board and Management Changes

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for US Patent Application 15/143,694 covering the use of cannabidiol (“CBD”) in the treatment of graft versus host disease (“GVHD”). Securing a patent for this proprietary technology represents an important step forward for the Company in its work focused on the treatment of this serious and life-threatening disease. https://kalytera.co/news/gvhd-us-patent-allowance/

Oct 10, 2017

Kalytera Announces Robert Farrell, J.D. as CEO; Additional Board and Management Changes

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that Robert Farrell, J.D., has been appointed as the Company’s Chief Executive Officer (“CEO”). Mr. Farrell previously held the position of Interim CEO. https://kalytera.co/news/kalytera-announces-robert-farrell-j-d-as-ceo-additional-board-and-management-changes/

Oct 02, 2017

Kalytera Receives IRB Approval for Proposed Phase 2 Study Evaluating CBD in the Prevention of Graft versus Host Disease

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced that it has received approval from the Institutional Review Board (“IRB”) at one of two clinical sites in Israel to commence a Phase 2 study to evaluate cannabidiol (“CBD”) for the prevention of GvHD. https://kalytera.co/news/first-irb-approval-phase-2-cbd-gvhd-study/

Aug 31, 2017

Kalytera Reports Second Quarter 2017 Financial Results

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today reported financial results for the quarter ended June 30, 2017. (All dollars U.S. unless otherwise noted.) https://kalytera.co/news/q2-2017-financial-results/

Aug 14, 2017

Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced that it has submitted an application to the Institutional Review Boards (“IRB”) of two clinical sites in Israel to commence a Phase 2 study to evaluate cannabidiol (“CBD”) for the prevention of GvHD. https://kalytera.co/news/irb-gvhd-phase-2-study-protocol/

Jul 22, 2017

Kalytera Announces Management Changes and Expansion of Leadership Team

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced that Andrew L. Salzman, M.D., who previously served as Kalytera’s Chief Executive Officer and Chief Medical Officer, and as a member of Kalytera’s Board of Directors, will be leaving the Company, effective June 21, 2017. Robert Farrell, J.D., President and CFO of Kalytera, will assume the role of interim Chief Executive Officer (“CEO”). Concurrent with Mr. Farrell’s appointment as interim CEO, the Company has expanded its senior management team with three new appointments. https://kalytera.co/news/management-changes-and-expansion-of-leadership-team/

May 31, 2017

Kalytera Reports First Quarter 2017 Financial Results

First Quarter 2017 Result Highlights

Working capital totaled $1.8 million, including cash and cash equivalents of $3.1 million, as of March 31, 2017, compared with $2.9 million and $673,000, respectively, as of December 31, 2016. https://kalytera.co/news/q1-2017-financial-results/

May 26, 2017

Kalytera Announces Changes to its Board of Directors

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease (“GvHD”), today announced the appointment of Ronald P. Erickson as Interim Chairman of its Board of Directors. Kalytera also announced the resignations of Jerome B. Zeldis, M.D., Ph.D., Director, and David Stefansky, Chairman. https://kalytera.co/news/changes-to-bod/​

May 02, 2017

Kalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook

Kalytera Therapeutics, Inc. (TSXV: KALY) (OTCQB: KALTF), a clinical-stage biopharmaceutical company developing cannabinoid-derived therapeutics for Graft versus Host Disease (“GvHD”) and certain other disorders, today reported its Fiscal Year 2016 results and provided a corporate update and outlook for 2017. (All dollars U.S. unless otherwise noted.) https://kalytera.co/news/kalytera-reports-fy-2016-results-provides-corporate-update-and-2017-outlook/

Apr 25, 2017

Kalytera Identifies Sites for Planned GvHD Clinical Trials

Kalytera Therapeutics, Inc. (TSXV: KALY), a clinical-stage biopharmaceutical company developing next-generation cannabinoid-derived therapeutics, today announced that it has developed the multi-center location component of the plan for the proposed clinical trials to evaluate cannabidiol (“CBD”) for the prevention and treatment of Graft versus Host Disease (“GvHD”). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization. https://kalytera.co/news/kalytera-identifies-sites-for-planned-gvhd-clinical-trials/

Apr 17, 2017

Kalytera Applies for $5 Million R&D Grant from IIA

Kalytera Therapeutics, Inc. (TSXV: KALY), a clinical stage biopharmaceutical company developing next generation cannabinoid-derived therapeutics, today announced it has applied for a $5 million grant from the Israel Innovation Authority (“IIA”) to fund development of its portfolio of novel cannabidiol (“CBD”) prodrugs. https://kalytera.co/news/kalytera-applies-for-5-million-rd-grant-from-iia/

Mar 17, 2017

Kalytera Therapeutics Appoints Pini Ben-Elazar to Board of Directors

Kalytera Therapeutics, Inc. (TSXV: KALY) today announced that Mr. Pini Ben-Elazar has been appointed to Kalytera’s Board of Directors. In connection with Kalytera’s recent acquisition of Talent Biotechs, Ltd., the selling shareholders of Talent had the right to nominate a person to join Kalytera’s Board of Directors. The selling shareholders nominated Mr. Ben-Elazar. https://kalytera.co/news/kalytera-therapeutics-appoints-pini-ben-elazar-to-board-of-directors/

Feb 22, 2017

Kalytera Therapeutics Announces Encouraging Results of a Phase 2a Clinical Study for the Treatment of Acute Graft versus Host Disease

Kalytera Therapeutics, Inc. (TSXV: KALY) (“Kalytera”) is pleased to announce encouraging results from a Phase 2a study evaluating the safety and efficacy of cannabidiol (“CBD”), a primary constituent of the marijuana plant, for the treatment of acute (Grade 3-4) Graft versus Host Disease (“GvHD”).https://kalytera.co/news/kalytera-therapeutics-announces-encouraging-results-of-a-phase-2a-clinical-study-for-the-treatment-of-acute-graft-versus-host-disease/

Feb 16, 2017

Kalytera Therapeutics Completes Acquisition of Talent Biotechs

Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) announced today that it has successfully completed the previously announced acquisition (the “Acquisition”) of Talent Biotechs Ltd. (“Talent”), strengthening Kalytera’s position as an emerging market leader in cannabidiol (“CBD”) pharmaceuticals. Talent is a privately held, Israeli-based company evaluating the use of CBD to prevent and treat Graft versus Host Disease (“GvHD”). https://kalytera.co/news/kalytera-completes-acquisition-of-talent-biotechs/

Feb 07, 2017

Kalytera Announces Closing of First Tranche of Brokered Private Placement

Kalytera Therapeutics, Inc. (TSXV:KALY) (the “Company” or “Kalytera”) is pleased to announce a first tranche (“First Tranche”) closing of its previously announced brokered private placement offering (the “Offering”) of common shares (the “Common Shares”) of the Company. The First Tranche closing consisted of the issuance of 29,833,300 Common Shares at a price of CDN$0.45 per Common Share (the “Offering Price”) for gross proceeds of CDN$13,424,985. Clarus Securities Inc., as lead agent, together with Haywood Securities Inc. and Canaccord Genuity Corp. https://kalytera.co/news/kalytera-announces-closing-of-first-tranche-of-brokered-private-placement/

Jan 24, 2017

Kalytera Announces Revised and Upsized Private Placement Terms

What's this item about? What makes it interesting? Write a catchy description to grab your audience's attention...

1 / 1

Please reload

© 2020 All Rights Reserved. Katan Associates International.

  • LinkedIn - Grey Circle
  • Twitter - Grey Circle
  • Facebook - Grey Circle